AML
Showing NaN - NaN of 10
Acute Myelogenous Leukemia, AML Trial in Worldwide (Venetoclax, Cytarabine)
Completed
- Acute Myelogenous Leukemia
- AML
-
Kansas City, Kansas
- +8 more
Aug 3, 2022
Hematologic Malignancy, AML, ALL Trial in Australia, United States (Tagraxofusp, Fludarabine, Cytarabine)
Not yet recruiting
- Hematologic Malignancy
- +10 more
- Tagraxofusp
- +8 more
-
Los Angeles, California
- +28 more
Jul 26, 2022
AML Trial in Worldwide (Flotetuzumab dose escalation, Flotetuzumab dose expansion, Ruxolitinib)
Active, not recruiting
- AML
- Flotetuzumab dose escalation
- +2 more
-
Duarte, California
- +42 more
Mar 7, 2022
AML Trial in Puerto Rico, United States (Cytarabine (Phase 1 only), Lintuzumab-Ac225, Furosemide (Phase 1 only))
Completed
- AML
- Cytarabine (Phase 1 only)
- +3 more
-
Los Angeles, California
- +16 more
Feb 22, 2022
Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute Trial in Canada, United States (Iomab-B, Conventional
Active, not recruiting
- Acute Myeloid Leukemia
- +8 more
- Iomab-B
- +2 more
-
Gilbert, Arizona
- +23 more
Feb 22, 2022
AML, MDS Trial in United States (APVO436)
Recruiting
- AML
- MDS
- APVO436
-
San Francisco, California
- +11 more
Feb 8, 2022
